Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cilo Cybin HoldingsJSE:CCC 7 PB Ratio is 2.24 as of Aug. 02, 2026. GuruFocus rates JSE:CCC with a GF Score™ of 7/100. The stock has 1 warning sign investors should review. Among 923 Drug Manufacturers companies, Cilo Cybin Holdings ranks worse than 57.42% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cilo Cybin Holdings PB Ratio Related Terms
Cilo Cybin Holdings PB Ratio Historical Data
* Premium members only.
The historical data trend for Cilo Cybin Holdings's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cilo Cybin Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cilo Cybin Holdings PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cilo Cybin Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cilo Cybin Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cilo Cybin Holdings (JSE:CCC) has a PB Ratio of 2.24 as of Aug. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cilo Cybin Holdings and its competitors. According to the industry distribution chart, Cilo Cybin Holdings ranks #530 out of 923 companies in the Drug Manufacturers industry, placing it in the top 57.4%.
Is Cilo Cybin Holdings' PB Ratio too high?
Cilo Cybin Holdings' current PB Ratio is 2.24. The Drug Manufacturers industry median PB Ratio is 1.88. Cilo Cybin Holdings' value of 2.24 is 19.1% above this industry median. Based on the distribution chart, Cilo Cybin Holdings ranks #530 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cilo Cybin Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Cilo Cybin Holdings' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cilo Cybin Holdings ranks #530 out of 923 companies for PB Ratio. This places Cilo Cybin Holdings in the lower half of its industry. The industry median PB Ratio is 1.88. Cilo Cybin Holdings' value of 2.24 is 19.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cilo Cybin Holdings's current PB Ratio of 2.24 is 19.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cilo Cybin Holdings and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cilo Cybin Holdings's current PB Ratio is 2.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cilo Cybin Holdings stock overvalued right now?
Cilo Cybin Holdings (JSE:CCC) has a current PB Ratio of 2.24. The current PB Ratio is 2.24 and 19.1% above the Drug Manufacturers industry median of 1.88. Cilo Cybin Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cilo Cybin Holdings (JSE:CCC), the current PB Ratio is 2.24 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cilo Cybin Holdings Ltd is engaged in identifying viable investments in Biotech, Biohacking and Pharmaceutical businesses. It offers products and services in the medical cannabis sector.
7GF Score
Get the complete analysis for JSE:CCC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:CCC has been successfully added to your 
